Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)

Tuesday, September 11, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

PARSIPPANY, N.J., Sept. 11 Validus Pharmaceuticals, Inc.announced today that it has acquired the unique Bipolar Disorder treatment,Equetro(R) (carbamazepine) extended release capsules, from Shire plc.

EQUETRO(R) is a treatment for the acute manic and mixed episodesassociated with Bipolar-1 Disorder -- a condition where patients experienceextended periods of exaggerated highs in addition to the extended lowscommonly associated with Bipolar Disorder. Equetro's patented advanced drugdelivery technology also provides patients with the convenience of twice-dailydosing.

"This is a watershed moment in the commercialization of ValidusPharmaceuticals" stated James Hunter, Validus President & CEO. "Equetro(R)provides mental health professionals with an important treatment option in themanagement of Bipolar Disorder. Equetro(R) also fits well within our growingproduct portfolio which includes Marplan(R) (isocarboxazid), the classic MAO-inhibitor for treatment-resistant depression."

Validus Pharmaceuticals will begin active promotion of Equetro(R) duringthe U.S. Psychiatric & Mental Health Congress -- one of the nation's largestgatherings of mental health professionals -- in Orlando, FL in early October.

About Validus Pharmaceuticals:

Validus Pharmaceuticals is a specialty pharmaceutical company founded inParsippany, NJ in 2007 to serve the unmet needs of patients with centralnervous system (CNS) diseases. The company pursues this mission with targetedand focused marketing efforts and active acquisition and in-licensing programsaimed at underutilized CNS products that have important future potential.Validus is a portfolio company of the Konanda Pharma Fund I, L.P. in New YorkCity. Please log-on to for additionalinformation.

About Marplan(R)

Please go to the Marplan(R) website for FullPrescribing Information, including BOXED WARNINGS regarding increased risk ofsuicidality in children and adolescents. MAO-inhibitors are contraindicatedwith certain drugs, and potential hypertensive crises may occur with tyraminecontaining foods. As with all antidepressants, patients should be observedclosely for clinical worsening, suicidality, and unusual changes in behavior,especially within the first few months of therapy.

About Equetro(R)

Please see complete Prescribing Information for Equetro at EQUETRO(R) contains carbamazepine. If you arecurrently taking another medication that contains carbamazepine, do not begintaking Equetro(R) without discussing this with your healthcare provider.Products that contain carbamazepine have been associated with rare but serioustypes of blood disorders. People with Bipolar Disorder have an increased riskfor suicide. It is important to discuss risk factors for suicide with yourhealthcare provider.

About Konanda Pharma Fund I, L.P.

Konanda Pharma Fund I, L.P. is an investment fund that is managed byKonanda Pharma Partners, LLC, based in New York City. The Fund acquiresmature branded drugs through portfolio companies which it owns and operates.Please log-on to for additional information.

SOURCE Validus Pharmaceuticals, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store